MedTech Strategist’s Post

View organization page for MedTech Strategist, graphic

11,518 followers

Osteoarthritis, one of the most common and debilitating chronic diseases, affects more than 30 million Americans, a number that is expected to increase exponentially as the population ages. Therapeutic options are limited. Current approaches start with nonpharmacological treatments such as walking aids, weight loss, and physical therapy, followed by acetaminophen and NSAIDS. Pioneers working on gene therapies for osteoarthritis and other chronic joint conditions won the prestigious OREF Award for 2024 at this year’s AAOS. One of the winners, Christopher Evans, PhD, discusses 30 years of research leading up to the founding of Genascence Corporation, which is now in clinical trials for a gene therapy for OA: https://bit.ly/3VDAh3R #medtech #osteoarthritis #chronicdisease #jointcondition #genetherapy

  • Osteoarthritis, one of the most common and debilitating chronic diseases, affects more than 30 million Americans, a number that is expected to increase exponentially as the population ages. Therapeutic options are limited.



Current approaches start with nonpharmacological treatments such as walking aids, weight loss, and physical therapy, followed by acetaminophen and NSAIDS.



Pioneers working on gene therapies for osteoarthritis and other chronic joint conditions won the prestigious OREF Award for 2024 at this year’s AAOS. One of the winners, Christopher Evans, PhD, discusses 30 years of research leading up to the founding of Genascence Corporation, which is now in clinical trials for a gene therapy for OA: https://bit.ly/3VDAh3R



#medtech #osteoarthritis #chronicdisease #jointcondition #genetherapy

To view or add a comment, sign in

Explore topics